Healthcare provider profile · identity verified

Mark R. Thiele, MD

Allopathic & Osteopathic Physicians|Family Medicine · HENDERSON, NV · NPI 1467593715

Profile state: payments and partd Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

CMS Open Payments records show Mark R. Thiele, MD received $199.04 in general payments during 2025 across 4 reported records.

MOXIMED, INC accounted for 56.0% of that reported general-payment amount.

The Open Payments records used for this analysis explicitly named 2 associated products.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

$199.04

4 reported records · 2 companies

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Who paid this doctor?

Companies in 2025 General Payments

Reported company	Canonical company	Amount	Share	Records	Year
MOXIMED, INC	Unresolved — no canonical attribution shown	$111.37	56.0%	2	2025
Stryker Corporation	Unresolved — no canonical attribution shown	$87.67	44.0%	2	2025

What were the payments for?

Payment categories

Category	Amount	Records
Food and Beverage	$159.91	3
Travel and Lodging	$39.13	1

A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.

Analysis 1 · Payment-linked products

Products named in Open Payments records

Reported product	Type	Reported company	Related amount*	Records	Year
MISHA KNEE SYSTEM, SMALL, LEFT Normalized: misha knee system small left	Device	MOXIMED, INC	$111.37	2	2025
Source payment records 2025-08-16 · MOXIMED, INC · $54.29 · Open Payments source 2025-08-16 · MOXIMED, INC · $57.08 · Open Payments source
BLUEPRINT PATIENT SPECIFIC INSTRUMENTATION Normalized: blueprint patient specific instrumentation	Device	Stryker Corporation	$87.67	2	2025
Source payment records 2025-02-12 · Stryker Corporation · $39.13 · Open Payments source 2025-02-22 · Stryker Corporation · $48.54 · Open Payments source

* Product-associated amounts are non-additive because one payment record may name more than one product.

These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.

Public prescribing for products named in payments

No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

None of this doctor’s payer companies has same-entity product evidence that passes the publication threshold. The site does not infer company ownership, affiliates, or generic manufacturers.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Atorvastatin Calcium	Atorvastatin Calcium	588	196
Rosuvastatin Calcium	Rosuvastatin Calcium	568	213
Lisinopril	Lisinopril	430	140
Levothyroxine Sodium	Levothyroxine Sodium	408	124
Amlodipine Besylate	Amlodipine Besylate	389	137
Losartan Potassium	Losartan Potassium	315	102
Omeprazole	Omeprazole	231	78
Metoprolol Succinate	Metoprolol Succinate	199	68
Metformin Hcl	Metformin Hcl	198	69
Pantoprazole Sodium	Pantoprazole Sodium	180	58
Tamsulosin Hcl	Tamsulosin Hcl	177	59
Gabapentin	Gabapentin	156	59
Simvastatin	Simvastatin	144	43
Eliquis	Apixaban	137	44
Albuterol Sulfate Hfa	Albuterol Sulfate	135	70
Hydrochlorothiazide	Hydrochlorothiazide	119	36
Carvedilol	Carvedilol	117	35
Sertraline Hcl	Sertraline Hcl	117	37
Allopurinol	Allopurinol	109	32
Metoprolol Tartrate	Metoprolol Tartrate	104	38
Clopidogrel	Clopidogrel Bisulfate	102	32
Trazodone Hcl	Trazodone Hcl	100	38
Alprazolam	Alprazolam	98	23
Baclofen	Baclofen	95	47
Metformin Hcl Er	Metformin Hcl	95	38
Montelukast Sodium	Montelukast Sodium	92	30
Alendronate Sodium	Alendronate Sodium	91	24
Meloxicam	Meloxicam	82	33
Escitalopram Oxalate	Escitalopram Oxalate	79	23
Fluticasone Propionate	Fluticasone Propionate	79	28
Losartan-Hydrochlorothiazide	Losartan/Hydrochlorothiazide	74	25
Lisinopril-Hydrochlorothiazide	Lisinopril/Hydrochlorothiazide	73	24
Zolpidem Tartrate	Zolpidem Tartrate	72	15
Tramadol Hcl	Tramadol Hcl	66	17
Hydroxyzine Hcl	Hydroxyzine Hcl	62	24
Triamcinolone Acetonide	Triamcinolone Acetonide	61	21
Duloxetine Hcl	Duloxetine Hcl	60	22
Glipizide	Glipizide	60	15
Furosemide	Furosemide	58	22
Pravastatin Sodium	Pravastatin Sodium	58	17
Glipizide Er	Glipizide	52	18
Ozempic	Semaglutide	52	13
Donepezil Hcl	Donepezil Hcl	51	13
Finasteride	Finasteride	51	18
Pioglitazone Hcl	Pioglitazone Hcl	48	20
Warfarin Sodium	Warfarin Sodium	48	suppressed
Prednisone	Prednisone	47	38
Synjardy Xr	Empagliflozin/Metformin Hcl	47	18
Potassium Chloride	Potassium Chloride	45	17
Famotidine	Famotidine	43	16
Ibuprofen	Ibuprofen	42	19
Lorazepam	Lorazepam	42	suppressed
Citalopram Hbr	Citalopram Hydrobromide	40	15
Jardiance	Empagliflozin	39	13
Paroxetine Hcl	Paroxetine Hcl	39	suppressed
Tizanidine Hcl	Tizanidine Hcl	39	11
Oxybutynin Chloride Er	Oxybutynin Chloride	38	14
Sumatriptan Succinate	Sumatriptan Succinate	37	suppressed
Glimepiride	Glimepiride	36	suppressed
Ropinirole Hcl	Ropinirole Hcl	35	13
Sildenafil Citrate	Sildenafil Citrate	35	12
Sulfamethoxazole-Trimethoprim	Sulfamethoxazole/Trimethoprim	35	28
Ezetimibe	Ezetimibe	33	11
Memantine Hcl	Memantine Hcl	33	suppressed
Trelegy Ellipta	Fluticasone/Umeclidin/Vilanter	32	12
Lantus Solostar	Insulin Glargine,hum.Rec.Anlog	31	11
Atenolol	Atenolol	30	15
Dicyclomine Hcl	Dicyclomine Hcl	28	11
Mupirocin	Mupirocin	28	21
Hydralazine Hcl	Hydralazine Hcl	27	11
Nortriptyline Hcl	Nortriptyline Hcl	27	suppressed
Oxybutynin Chloride	Oxybutynin Chloride	26	suppressed
Acyclovir	Acyclovir	25	suppressed
Bupropion Xl	Bupropion Hcl	25	suppressed
Clotrimazole-Betamethasone	Clotrimazole/Betamethasone Dip	25	22
Stiolto Respimat	Tiotropium Br/Olodaterol Hcl	25	suppressed
Cyclobenzaprine Hcl	Cyclobenzaprine Hcl	24	suppressed
Amitriptyline Hcl	Amitriptyline Hcl	23	suppressed
Fluticasone-Salmeterol	Fluticasone Propion/Salmeterol	23	suppressed
Nifedipine Er	Nifedipine	23	suppressed
Valsartan	Valsartan	23	suppressed
Fenofibrate	Fenofibrate	21	suppressed
Fluoxetine Hcl	Fluoxetine Hcl	21	suppressed
Isosorbide Mononitrate Er	Isosorbide Mononitrate	21	suppressed
Pramipexole Dihydrochloride	Pramipexole Di-Hcl	21	suppressed
Celecoxib	Celecoxib	20	suppressed
Clonazepam	Clonazepam	20	suppressed
Diclofenac Sodium	Diclofenac Sodium	20	15
Xarelto	Rivaroxaban	20	suppressed
Amlodipine Besylate-Benazepril	Amlodipine Besylate/Benazepril	19	suppressed
Clonidine Hcl	Clonidine Hcl	19	15
Fenofibrate	Fenofibrate Nanocrystallized	19	suppressed
Hydrocodone-Acetaminophen	Hydrocodone/Acetaminophen	19	17
Methylprednisolone	Methylprednisolone	19	18
Quetiapine Fumarate	Quetiapine Fumarate	19	suppressed
Valacyclovir	Valacyclovir Hcl	19	suppressed
Breo Ellipta	Fluticasone/Vilanterol	18	suppressed
Buspirone Hcl	Buspirone Hcl	18	suppressed
Mirtazapine	Mirtazapine	18	suppressed
Pregabalin	Pregabalin	18	suppressed
Anoro Ellipta	Umeclidinium Brm/Vilanterol Tr	17	suppressed
Lovastatin	Lovastatin	17	suppressed
Meclizine Hcl	Meclizine Hcl	17	11
Nystatin	Nystatin	17	suppressed
Terazosin Hcl	Terazosin Hcl	17	suppressed
Ramipril	Ramipril	16	suppressed
Valsartan-Hydrochlorothiazide	Valsartan/Hydrochlorothiazide	16	suppressed
Benazepril Hcl	Benazepril Hcl	15	suppressed
Nitroglycerin	Nitroglycerin	15	suppressed
Oxycodone-Acetaminophen	Oxycodone Hcl/Acetaminophen	15	suppressed
Temazepam	Temazepam	15	suppressed
Ibu	Ibuprofen	14	suppressed
Levetiracetam	Levetiracetam	14	suppressed
Nitrofurantoin Mono-Macro	Nitrofurantoin Monohyd/M-Cryst	14	13
Propranolol Hcl	Propranolol Hcl	14	suppressed
Spironolactone	Spironolactone	14	suppressed
Cilostazol	Cilostazol	13	suppressed
Estradiol	Estradiol	13	suppressed
Ondansetron Hcl	Ondansetron Hcl	13	suppressed
Primidone	Primidone	13	suppressed
Triamterene-Hydrochlorothiazid	Triamterene/Hydrochlorothiazid	13	suppressed
Benztropine Mesylate	Benztropine Mesylate	12	suppressed
Ibandronate Sodium	Ibandronate Sodium	12	suppressed
Irbesartan	Irbesartan	12	suppressed
Methocarbamol	Methocarbamol	12	suppressed
Spiriva Respimat	Tiotropium Bromide	12	suppressed
Synthroid	Levothyroxine Sodium	12	suppressed
Azithromycin	Azithromycin	11	11
Eszopiclone	Eszopiclone	11	suppressed
Insulin Lispro Protamine Mix	Insulin Lispro Protamin/Lispro	11	suppressed
Ketoconazole	Ketoconazole	11	suppressed
Telmisartan	Telmisartan	11	suppressed
Venlafaxine Hcl Er	Venlafaxine Hcl	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	$199.04 · 4 records	MOXIMED, INC	BLUEPRINT PATIENT SPECIFIC INSTRUMENTATION, MISHA KNEE SYSTEM, SMALL, LEFT	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error